Breaking News

Biogen Idec 3Q

October 23, 2007

Biogen Idec

3Q Revenues: $789 million (+12%)

3Q Earnings: $119 million (-24%)

YTD Revenues: $2.3 billion (+15%)

YTD Earnings: $437 million (+301%)

Comments: Avonex sales leveled off, up 2% to $455 million, while BI's share of Rituxan revenues rose 15% to $235 million. During the quarter, the company's named Paul Clancy to the role of chief financial officer. Two months later, BI's board authorized management to look for a buyer for the company.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks